Hillhurst Biopharmaceuticals, Inc.
Publicly observedMontrose, United States
Seen in a public record (e.g. a government grant database); not otherwise verified.
Details and provenance
| Item | Value | Source | Status |
|---|---|---|---|
| Country | US | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
| City / locality | Montrose | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
| Name | Hillhurst Biopharmaceuticals, Inc. | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
| UEI (U.S. federal entity ID) | G5YJYCGDUZD7 | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
Recorded events
- Grant1 Sept 2021Publicly observed
NIH SBIR/STTR award: HBI-002 to Treat Diabetic Retinopathy
USD 961,240.00 · National Eye Institute · Source: NIH RePORTER (opens in a new tab)
- Grant7 Apr 2016Publicly observed
NIH SBIR/STTR award: HBI-002 to Prevent Vaso-Occlusive Crises in Sickle Cell Disease
USD 999,718.00 · National Heart Lung and Blood Institute · Source: NIH RePORTER (opens in a new tab)
Information only — not investment advice or an endorsement. Is this your company? Submit or update its details or request a correction.